GlaxoSmithKline is acquiring Maxinutrition, a UK company that manufactures protein-enhanced functional nutrition products, from Darwin Private Equity for £162m, including the repayment of outstanding debt. Maxinutrition is Europe’s leading sports
GlaxoSmithKline is acquiring Maxinutrition, a UK company that manufactures protein-enhanced functional nutrition products, from Darwin Private Equity for £162m, including the repayment of outstanding debt. Maxinutrition is Europe’s leading sports